Fig. 6
From: IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway
The effect of IMB0901 on the antitumor effect of doxorubicin in vitro and in vivo. a The effect of IMB0901 combined with doxorubicin on the cell survival rate of C26 cells. MTT assay was used to detect the cell survival rate of C26 cells after 24 h treatment with IMB0901 at various concentrations combined with doxorubicin. The values presented the mean ± SD from three experiments, each performed in triplicate. b The effect of IMB0901 on the MSTN expression change induced by doxorubicin in C2C12 myotubes. Western blotting was used to detect the expression of MSTN after 24-h treatment with IMB0901 and doxorubicin in C2C12 myotubes. The values were means ± SD from three experiments. *P < 0.05 compared to the control group, #P < 0.05 compared to the DOX group. c The body weights of BALB/c mice at day 0~20. Doxorubicin was administered twice with 0.2 ml each at a dose of 10 mg/kg via the intraperitoneal injection. d The carcass weights of BALB/c mice. e–h The mass of quadriceps, gastrocnemius muscles, WAT, and BAT in the C26 and doxorubicin model. There were four groups in this experiment: control, C26, C26 + DOX, and C26 + DOX + IMB0901. The data were means ± SD from 10 animals. *P < 0.05 and **P < 0.01 compared to the control group, #P < 0.05 and ##P < 0.01 compared to the C26 + DOX group